- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01468636
A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts
October 31, 2016 updated by: University of British Columbia
A Randomized Controlled Trial to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts
The purpose of this study is to examine the effect of 400 mg of oral zinc gluconate on genital warts.
Our hypothesis is that there will be a 10% difference in complete clearance of genital warts in the group randomized to oral plus standard of care compared to those randomized to placebo plus standard of care.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Clients presenting to the BCCDC STI clinic with genital warts will be randomized to either 400 mg zinc gluconate or placebo (200mg BID) for 8 weeks in addition to the standard of care.
Clinical assessment of warts and additional standard treatment will occur every 7-10 days for a maximum of 8 weeks.
A telephone call will occur at week 20 to determine if any of the warts have cleared or re-appeared.
The appearance of new warts will also be noted.
The proportion of subjects who have complete clearance of genital warts at 8 weeks will be compared between groups.
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4R4
- BC Centre for Disease Control
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults age 19 and over
- Clinical diagnosis of genital warts requiring treatment based on clinician evaluation
- Fluency in English
- Available within four days of the intended 8 week follow-up visit
Exclusion Criteria:
- Individuals under the age of 19
- Pregnant women
- Known contraindication to zinc Signs of copper/iron deficiency which include anemia and neutropenia which are characterized by tiredness, fatigue and light headedness.
- Diseases that alter zinc metabolism or absorption eg. type II diabetes mellitus, Crohn's disease, chronic leg ulcers
- Clients who are currently taking zinc for therapeutic purposes or have taken zinc in the last two months for therapeutic purposes
- Clients who have received standard of care treatment for their warts in the past month
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
200mg BID x 8 weeks
|
Active Comparator: Oral Zinc
|
200 mg BID of oral zinc gluconate x 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
complete clearance of genital warts
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Richard Lester, University of British Columbia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2011
Primary Completion (Actual)
January 1, 2012
Study Completion (Actual)
January 1, 2012
Study Registration Dates
First Submitted
November 7, 2011
First Submitted That Met QC Criteria
November 8, 2011
First Posted (Estimate)
November 9, 2011
Study Record Updates
Last Update Posted (Estimate)
November 2, 2016
Last Update Submitted That Met QC Criteria
October 31, 2016
Last Verified
October 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H11-01758 (Other Identifier: UBC IRB number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HPV
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingHPV Vaccine | HPVUnited States, Puerto Rico
-
Indiana UniversityMerck Sharp & Dohme LLCCompletedHPV Vaccine Attitudes | HPV Vaccine IntentionUnited States
-
Xijing HospitalEnrolling by invitationHPV Vaccination、HPV Related Diseases、Protective EfficacyChina
-
Global Alliance to Immunize Against AIDS Vaccine...Merck Sharp & Dohme LLCCompletedHPV-Related Cervical Carcinoma | HPV
-
Emory UniversityRecruiting
-
East Carolina UniversityRecruiting
-
University of FloridaNational Cancer Institute (NCI)Active, not recruiting
-
University of MinnesotaCompleted
-
Brigham and Women's HospitalNational Institutes of Health (NIH)Not yet recruiting
-
Memorial Sloan Kettering Cancer CenterHackensack Meridian Health; The City College of New YorkActive, not recruitingHPV VaccinationUnited States
Clinical Trials on Oral Zinc
-
Postgraduate Institute of Dental Sciences RohtakUnknown
-
Hormozgan University of Medical SciencesCompleted
-
Mansoura UniversityCompleted
-
Centre For International HealthAll India Institute of Medical Sciences, New DelhiCompleted
-
Dow University of Health SciencesCompleted
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI); American Lung AssociationCompleted
-
mariam hamoudaCompletedBenign Migratory GlossitisEgypt
-
Society for Applied StudiesIndian Council of Medical ResearchCompletedPneumonia | Sepsis | Diarrhea | Death | MeningitisIndia
-
Ferrer Internacional S.A.Axonal-BiostatemCompleted
-
University of IowaTinnitus Research InitiativeCompleted